Evidence map›Paper›PMID 22988452›Full record

ArticleDermatology research and practice2012

The infant skin barrier: can we preserve, protect, and enhance the barrier?

Lorena S Telofski, A Peter Morello, M Catherine Mack Correa, Georgios N Stamatas

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Dermatology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05589038 (A Randomized, Evaluator-Blinded, Clinical Evaluation of a Regimen of a Baby Wash/Shampoo and Baby Lotion Versus Baby Wash/Shampoo Alone for Tolerability and Impact on Skin Barrier and Microbiome on Newborns), which is not on this map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
7.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05589038 naterminatednot on this mapstarted 2022, after this paper: background citation

A Randomized, Evaluator-Blinded, Clinical Evaluation of a Regimen of a Baby Wash/Shampoo and Baby Lotion Versus Baby Wash/Shampoo Alone for Tolerability and Impact on Skin Barrier and Microbiome on Newborns

TypeinterventionalSponsorJohnson & Johnson Consumer Inc. (J&JCI)Ran2022 to 2023Enrolled53ConditionsHealthyArmsBaby Wash/Shampoo, Baby Lotion
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 106 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Nanotechnology in Infantile Hemangioma Management.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  7. Skin Care Practices in Indian Newborns and Infants: Current Scenario.Pediatric health, medicine and therapeutics · 2025
    Review
  8. Skin Barrier Function in Neonates and Infants.Allergy, asthma & immunology research · 2025
    Review
  9. Antioxidants (Basel, Switzerland) · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Pediatric contact allergens in the neonatal intensive care unit.Journal of perinatology : official journal of the California Perinatal Association · 2020
    Article
  20. A quantitative cross-sectional analysis of the melanin index in the skin of preterm newborns and its association with gestational age at birth.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2020
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Lorena S TelofskiJOHNSON & JOHNSON Consumer Companies, Inc., 199 Grandview Road, Skillman, NJ 08558, USA.
A Peter Morello
M Catherine Mack Correa
Georgios N Stamatas
Johnson & Johnson (United States) · USJohnson & Johnson (France) · FRScientific Solutions (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infant skin is different from adult in structure, function, and composition. Despite these differences, the skin barrier is competent at birth in healthy, full-term neonates. The primary focus of this paper is on the developing skin barrier in healthy, full-term neonates and infants. Additionally, a brief discussion of the properties of the skin barrier in premature neonates and infants with abnormal skin conditions (i.e., atopic dermatitis and eczema) is included. As infant skin continues to mature through the first years of life, it is important that skin care products (e.g., cleansers and emollients) are formulated appropriately. Ideally, products that are used on infants should not interfere with skin surface pH or perturb the skin barrier. For cleansers, this can be achieved by choosing the right type of surfactant, by blending surfactants, or by blending hydrophobically-modified polymers (HMPs) with surfactants to increase product mildness. Similarly, choosing the right type of oil for emollients is important. Unlike some vegetable oils, mineral oil is more stable and is not subject to oxidation and hydrolysis. Although emollients can improve the skin barrier, more studies are needed to determine the potential long-term benefits of using emollients on healthy, full-term neonates and infants.

Identifiers

PMID22988452
PMCPMC3439947
OpenAlexW1997806999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.